Comparing the efficacy and safety of medications to prevent nonsteroidal anti-inflammatory drug-induced ulcers in high-risk patients: A network meta-analysis
Digestive and Liver Disease · 2026-02 · 58 (2) · 197-205
DOI: 10.1016/j.dld.2025.11.012 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestive and Liver Disease, 2026-02. Verfasst von Xu Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Peptic Ulcer, Proton Pump Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The optimal strategy for preventing nonsteroidal anti-inflammatory drug-induced peptic ulcers in patients with prior peptic ulcers remains uncertain. We performed a systematic review and network meta-analysis of 22 randomized controlled trials (7,768 patients) on nonsteroidal anti-inflammatory drug users with a documented ulcer history to compare the efficacy and safety of medications for the prevention of these ulcers. The eligible interventions included proton pump inhibitors, potassium-competitive acid blockers, cyclooxygenase-2 inhibitors, prostaglandin analogs, histamine-2 receptor antagonists, and gastric mucosal protective agents. The primary outcomes were ulcer recurrence and bleeding. The safety outcomes included treatment-emergent adverse events and discontinuation owing to adverse events. Random-effects network models estimated the relative and absolute risks, numbers needed to treat, and rankings. Compared with placebo, cyclooxygenase-2 inhibitor plus proton pump inhibitor, potassium-competitive acid blocker, cyclooxygenase-2 inhibitor alone, and proton pump inhibitor monotherapy markedly reduced ulcer recurrence (numbers needed to treat = 5-6). Similar patterns were observed for bleeding prevention. Prostaglandin analogs increased adverse events and discontinuations. Proton pump inhibitor monotherapy remains the most evidence-based first-line strategy for these patients. Cyclooxygenase-2 inhibitor plus proton pump inhibitors or potassium-competitive acid blockers may provide additional benefits in very high-risk patients, but safety and cost considerations warrant caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China.
- Department of Rheumatology and Immunology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China. Electronic address: peidm1111@hotmail.com.
Zitieren
APA
Huang, X., Fang, Q., Zhou, L., Gong, C., & Pei, D. (2026). Comparing the efficacy and safety of medications to prevent nonsteroidal anti-inflammatory drug-induced ulcers in high-risk patients: A network meta-analysis. Digestive and Liver Disease, 58(2), 197-205. https://doi.org/10.1016/j.dld.2025.11.012
Vancouver
Huang X, Fang Q, Zhou L, Gong C, Pei D. Comparing the efficacy and safety of medications to prevent nonsteroidal anti-inflammatory drug-induced ulcers in high-risk patients: A network meta-analysis. Digestive and Liver Disease. 2026;58(2):197-205. doi:10.1016/j.dld.2025.11.012
BibTeX
@article{Huang2026,
author = {Huang, Xu and Fang, Qingying and Zhou, Liwei and Gong, Chenxi and Pei, Dongmei},
title = {Comparing the efficacy and safety of medications to prevent nonsteroidal anti-inflammatory drug-induced ulcers in high-risk patients: A network meta-analysis},
journal = {Digestive and Liver Disease},
year = {2026},
volume = {58},
number = {2},
pages = {197--205},
doi = {10.1016/j.dld.2025.11.012}
}
EUVIMED